Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 rollover study of lumacaftor + ivacaftor in cystic fibrosis
2015-001644-11Phase 3
- Sponsor
- Vertex Pharmaceuticals
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lumacaftor + ivacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Primary endpoint: Long-term safety and tolerability.
02
Drugs
lumacaftor + ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2015-001644-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001644-11.